Working… Menu

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03537651
Recruitment Status : Active, not recruiting
First Posted : May 25, 2018
Last Update Posted : November 30, 2020
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This study will evaluate the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in subjects with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: TEZ Drug: IVA Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation
Actual Study Start Date : April 25, 2018
Actual Primary Completion Date : October 28, 2020
Estimated Study Completion Date : September 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: TEZ + IVA

Subjects <30 kg will receive 50 mg TEZ/ 75 mg IVA as a FDC tablet in the morning and 75 mg IVA as a mono tablet in the evening.

Subjects >=30 kg will receive 100 mg TEZ/ 150 mg IVA FDC tablet in the morning and 150 mg IVA as a mono tablet in the evening.

Drug: TEZ
Fixed-dose Combination (FDC) tablet (TEZ/IVA)
Other Name: tezacaftor; VX-661

Drug: IVA
FDC tablet (TEZ/IVA)
Other Name: ivacaftor; VX-770

Primary Outcome Measures :
  1. Safety and tolerability of long-term TEZ/IVA treatment based on adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: from baseline through safety follow-up (up to 28 days after Last Dose at Week 96) ]

Secondary Outcome Measures :
  1. Absolute change in lung clearance index2.5 (LCI2.5) [ Time Frame: from baseline through 96 weeks ]
  2. Absolute change in sweat chloride [ Time Frame: from baseline through 96 weeks ]
  3. Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score [ Time Frame: from baseline through 96 weeks ]
  4. Absolute change in body mass index (BMI) [ Time Frame: from baseline through 96 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed the Week 24 Visit in Study 113 Part B or the Week 8 Visit in Study 115.
  • Eligible CFTR Mutation.

Exclusion Criteria:

  • Pregnant and nursing females.
  • History of poor compliance with study drug and/or procedures in a previous study as deemed by the investigator.
  • Ongoing participation in another study with investigational drug.

Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03537651

Show Show 55 study locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated Identifier: NCT03537651    
Other Study ID Numbers: VX17-661-116
2017-002968-40 ( EudraCT Number )
First Posted: May 25, 2018    Key Record Dates
Last Update Posted: November 30, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action